Acetohydroxamic Acid
A medication used to treat chronic urinary tract infections caused by bacteria that produce urease, an enzyme that breaks down urea and makes the urine alkaline, allowing kidney stones to form. By blocking urease, it prevents the bacteria from creating the alkaline environment they need to thrive and reduces the growth of certain types of kidney stones. It is typically used as a complement to antibiotics, not as a replacement, and requires monitoring for side effects including tremors and anemia.
Molecular Weight
75.0700 g/mol
LogP
-1.60
TPSA
49.30 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Inhibits bacterial urease, the enzyme that hydrolyzes urea to ammonia and carbon dioxide, reducing the alkalinization of urine that promotes stone formation and infection persistence.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial urease, the enzyme that hydrolyzes urea to ammonia and carbon dioxide, reducing the alkalinization of urine that promotes stone formation and infection persistence.
2D Structure
Cite this structure
Embed this structure
SMILES
CC(=O)NO
InChI
InChI=1S/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)
Molecular Formula
C2H5NO2
HBD / HBA
2 / 2
Rotatable Bonds
0
Heavy Atoms
5
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A medication used to treat chronic urinary tract infections caused by bacteria that produce urease, an enzyme that breaks down urea and makes the urine alkaline, allowing kidney stones to form. By blocking urease, it prevents the bacteria from creating the alkaline environment they need to thrive and reduces the growth of certain types of kidney stones. It is typically used as a complement to antibiotics, not as a replacement, and requires monitoring for side effects including tremors and anemia.
Inhibits bacterial urease, the enzyme that hydrolyzes urea to ammonia and carbon dioxide, reducing the alkalinization of urine that promotes stone formation and infection persistence.
Yes, Acetohydroxamic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL734. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 1990. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="acetohydroxamic-acid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/acetohydroxamic-acid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/acetohydroxamic-acid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/acetohydroxamic-acid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="acetohydroxamic-acid"></drugfyi-drug>